STLN Stock Price, Performance & Company Data

13:30

15:10

16:45

18:25

20:00

About Starling Oncology

Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.

Ticker: $STLN
Sector: Health

Primary listing: NASDAQ
Employees: 641

Headquarters: Cerritos, United States
Website: starlingoncology.com

STLN Metrics

BasicAdvanced

$631m

-$0.30

0.42

Bulls say / Bears say

Second quarter 2026 revenue grew 34.6% year-over-year to $161.3 million, driven by strong specialty pharmacy performance and growth in capitated lives (StockTitan)

Adjusted EBITDA turned positive at $0.2 million in Q2 2026 versus a loss of $4.1 million a year ago, reflecting improved operating leverage and cost management (StockTitan)

Starling secured its first delegated contracts outside Florida—Nevada, Oregon, and California exclusivity—adding approximately 230,000 capitated lives to its value-based care network (StockTitan)

Medical loss ratio on capitated contracts increased to 85.5% in Q2 2026 from 71.0% a year earlier, indicating rising care costs and margin pressure on value-based arrangements (StockTitan)

Full-year 2026 adjusted EBITDA guidance was narrowed to $2–$7 million from a prior range of $0–$9 million, curbing profitability upside and investor expectations (StockTitan)

Cash and cash equivalents of $41.1 million as of June 30, 2026 may provide limited runway given ongoing net losses and planned investments without additional financing (StockTitan)

Data summarised monthly by Lightyear AI. Last updated on 12 Aug 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Second quarter 2026 revenue grew 34.6% year-over-year to $161.3 million, driven by strong specialty pharmacy performance and growth in capitated lives (StockTitan)

Adjusted EBITDA turned positive at $0.2 million in Q2 2026 versus a loss of $4.1 million a year ago, reflecting improved operating leverage and cost management (StockTitan)

Starling secured its first delegated contracts outside Florida—Nevada, Oregon, and California exclusivity—adding approximately 230,000 capitated lives to its value-based care network (StockTitan)

Medical loss ratio on capitated contracts increased to 85.5% in Q2 2026 from 71.0% a year earlier, indicating rising care costs and margin pressure on value-based arrangements (StockTitan)

Full-year 2026 adjusted EBITDA guidance was narrowed to $2–$7 million from a prior range of $0–$9 million, curbing profitability upside and investor expectations (StockTitan)

Cash and cash equivalents of $41.1 million as of June 30, 2026 may provide limited runway given ongoing net losses and planned investments without additional financing (StockTitan)

Data summarised monthly by Lightyear AI. Last updated on 12 Aug 2026.

About Starling Oncology

STLN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy $STLN

Lightyear

Legal

Work with us

Bulls say / Bears say

Starling Oncology/$STLN

About Starling Oncology

STLN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Bulls say / Bears say